Drugs / WGb-0301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07349823 | Jan 2026 → Dec 2027 expected | autoimmune disease | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07332663 | Jan 2026 → Dec 2027 expected | B-cell neoplasm | Sichuan University | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WGb 0301 | “The experimental drug WGb 0301 injection is a CD19 based messenger ribonucleic acid (mRNA) therapeutic drug, formed by loading mRNA encoding CD19 receptor related proteins onto...” NCT07349823 ↗ |
| Action | Deplete | “demonstrated efficient B-cell clearance activity” NCT07332663 ↗ |
| Modality | Messenger RNA (mRNA) | “messenger RNA (mRNA) therapeutic mRNA drug” NCT07332663 ↗ |
| Route | Intramuscular | “through intravenous or intramuscular injection” NCT07332663 ↗ |
| Route | Intravenous | “through intravenous or intramuscular injection” NCT07332663 ↗ |
| Target | CD19 | “targeting CD19” NCT07332663 ↗ |